Compare GTLB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | LNTH |
|---|---|---|
| Founded | 2011 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 4.2B |
| IPO Year | 2021 | 2015 |
| Metric | GTLB | LNTH |
|---|---|---|
| Price | $39.92 | $66.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 6 |
| Target Price | $54.59 | ★ $77.33 |
| AVG Volume (30 Days) | ★ 5.5M | 1.0M |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | $906,253,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $26.43 | $0.01 |
| Revenue Next Year | $20.01 | $1.24 |
| P/E Ratio | ★ N/A | $27.84 |
| Revenue Growth | ★ 27.36 | 1.95 |
| 52 Week Low | $35.81 | $47.25 |
| 52 Week High | $74.18 | $111.29 |
| Indicator | GTLB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 72.55 |
| Support Level | $35.81 | $60.15 |
| Resistance Level | $41.55 | $64.40 |
| Average True Range (ATR) | 1.63 | 2.09 |
| MACD | 0.13 | 0.66 |
| Stochastic Oscillator | 48.09 | 94.44 |
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.